The Interplay Between CAR T Therapy and Antibody Engineering A Convergence of Immunotherapy
Description
In recent years, the landscape of cancer treatment has been profoundly reshaped by the emergence of immunotherapy strategies such as Chimeric Antigen Receptor T-cell (CAR-T) therapy and antibody engineering. These modalities represent two of the most promising fronts in the fight against cancer, leveraging the body’s immune system to recognize and destroy malignant cells. While CAR-T therapy involves reprogramming the patient's T cells to target tumor cells, antibody engineering focuses on creating highly specific antibodies that can bind to cancer-specific antigens and recruit immune effector functions. This article explores the interplay between these two technologies, highlighting how they complement each other and could potentially integrate to offer more effective cancer treatment solutions.
Stay curious, stay innovative. I'm Luke McLaughlin.
If you would like to learn more about this topic consider reading our full length articles on www.biotechnologyreviews.com
Or consider our podcast series on youtube or Spotify at our Biotechnology Reviews Channel.
Our articles are also available on our linkedin newsletter Biotechnology Reviews.
United States
